Zymeworks (ZYME) Q2 2024 earnings summary

Executive summary

• Achieved key regulatory milestones for zanidatamab, including FDA Priority Review in the US (PDUFA date November 29, 2024), EMA validation in Europe, and BLA acceptance in China, triggering an $8 million milestone payment from BeiGene.

• Advanced clinical pipeline with IND clearances for ZW171 and ZW191, with first-in-human studies planned for H2 2024; IND filings for ZW220 and ZW251 expected in 2025.

• Discontinued zanidatamab zovodotin (ZW49) program to focus on early-stage assets and reallocated resources; exploring partnership opportunities for Zani-Zovo.

• Strategic partnerships with Jazz and BeiGene provide milestone and royalty opportunities, supporting a projected cash runway into the second half of 2027.

• Appointment of Leone Patterson as EVP, CBO, and CFO effective September 1, 2024.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $395.9 million as of June 30, 2024, with projected runway into 2H 2027.

• Revenue for the six months ended June 30, 2024, was $29.3 million, down from $42.6 million in 2023; Q2 2024 revenue was $19.2 million, up 174% year-over-year.

• Net loss for the six months ended June 30, 2024, was $69.3 million ($0.91 per share), compared to $75.5 million in 2023.

• Operating expenses decreased year-over-year, with R&D and G&A expenses down significantly; $17.3 million impairment charge recorded for zanidatamab zovodotin discontinuation.

Outlook and guidance

• Cash resources and anticipated milestone payments expected to fund operations into the second half of 2027.

• Top-line progression-free survival data from the pivotal HERIZON-GEA-01 trial expected in Q2 2025.

• IND filings for ZW220 and ZW251 planned for 2025; nomination of a tri-specific T-cell engager candidate expected later in 2024.